

Source details

Journal of Basic and Clinical Physiology and Pharmacology

CiteScore 2020 ⓘ
2.7

Formerly known as: Reviews in Clinical and Basic Pharmacology

Scopus coverage years: from 1985 to 1988, from 1990 to 2021

Publisher: Walter de Gruyter

SJR 2020 ⓘ
0.414

ISSN: 0792-6855 E-ISSN: 2191-0286

- Subject area:
- Pharmacology, Toxicology and Pharmaceutics: Pharmacology
 - Pharmacology, Toxicology and Pharmaceutics: Drug Discovery
 - Biochemistry, Genetics and Molecular Biology: Physiology

SNIP 2020 ⓘ
0.682

Source type: Journal

[View all documents >](#)
[Set document alert](#)
[📁 Save to source list](#)
[Source Homepage](#)

[CiteScore](#)
[CiteScore rank & trend](#)
[Scopus content coverage](#)

i Improved CiteScore methodology ✕

CiteScore 2020 counts the citations received in 2017-2020 to articles, reviews, conference papers, book chapters and data papers published in 2017-2020, and divides this by the number of publications published in 2017-2020. [Learn more >](#)

CiteScore 2020 ▼

$$2.7 = \frac{859 \text{ Citations 2017 - 2020}}{323 \text{ Documents 2017 - 2020}}$$

Calculated on 05 May, 2021

CiteScoreTracker 2021 ⓘ

$$2.5 = \frac{999 \text{ Citations to date}}{404 \text{ Documents to date}}$$

Last updated on 05 January, 2022 • Updated monthly


CiteScore rank 2020 ⓘ

Category	Rank	Percentile
Pharmacology, Toxicology and Pharmaceutics — Pharmacology	#185/297	37th
Pharmacology, Toxicology and Pharmaceutics — Drug Discovery	#96/145	34th

[View CiteScore methodology >](#)
[CiteScore FAQ >](#)
[Add CiteScore to your site 🌐](#)

SJR Scimago Journal & Country Rank
SCIMAGO INSTITUTIONS RANKINGS

Home
Journal Rankings
Country Rankings
Viz Tools
Help
About Us



Submit Your Manuscript With Us

Learn More About How to Publish and our Partnership with Hindawi.

Hindawi
Open

Journal of Basic and Clinical Physiology and Pharmacology

COUNTRY	SUBJECT AREA AND CATEGORY	PUBLISHER	H-INDEX
Germany 	Biochemistry, Genetics and Molecular Biology - Physiology Medicine - Medicine (miscellaneous) Pharmacology, Toxicology and Pharmaceutics - Drug Discovery - Pharmacology	Walter de Gruyter GmbH	33
PUBLICATION TYPE	ISSN	COVERAGE	INFORMATION
Journals	07926855, 21910286	1985-1988, 1990-2020	Homepage How to publish in this journal m.horowitz@mail.huji.ac.il

SCOPE

The Journal of Basic and Clinical Physiology and Pharmacology (JBCPP) is a peer-reviewed bi-monthly published journal in experimental medicine. JBCPP publishes novel research in the physiological and pharmacological sciences, including brain research; cardiovascular-pulmonary interactions; exercise; thermal control; haematology; immune response; inflammation; metabolism; oxidative stress; and phytotherapy. As the borders between physiology, pharmacology and biochemistry become increasingly blurred, we also welcome papers using cutting-edge techniques in cellular and/or molecular biology to link descriptive or behavioral studies with cellular and molecular mechanisms underlying the integrative processes. Topics: Behavior and Neuroprotection, Reproduction, Genotoxicity and Cytotoxicity, Vascular Conditions, Cardiovascular Function, Cardiovascular-Pulmonary Interactions, Oxidative Stress, Metabolism, Immune Response, Hematological Profile, Inflammation, Infection, Phytotherapy.

 Join the conversation about this journal

 American Journal Experts



AJE: English Editing & Author Services for Research Publication

Open

 American Journal Experts



AJE: English Editing & Author Services for Research Publication

Open



AJE: English Editing & Author Services for Research Publication

Open

AJE American Journal Experts

FIND SIMILAR JOURNALS


Archives of Physiology and Biochemistry <small>ISR</small> 65% <small>similarity</small>	International Journal of Pharmacology <small>PAK</small> 62% <small>similarity</small>	Pathophysiology <small>CHE</small> 60% <small>similarity</small>	Tropical Journal of Pharmaceutical Research <small>IND</small> 60% <small>similarity</small>	Iranian Journal of Basic Medical Sciences <small>IRN</small> 59% <small>similarity</small>
---	---	---	---	---



AJE: English Editing & Author Services for Research Publication

Open

AJE American Journal Experts



Journal of Basic and Clinical Physiology and...
 Drug Discovery
 Q3
 SJR 2020 0.41
 powered by scimagojr.com

Show this widget in your own website
 Just copy the code below and paste within your html code:

SCImago Graphica
 Explore, visually communicate and make sense of data with our new free tool.
 Get it

DE GRUYTER

ISSN 1535-768X (print)
ISSN 1535-7698 (online)

JOURNAL OF BASIC AND CLINICAL PHYSIOLOGY AND PHARMACOLOGY

EDITED BY
Michael Honninger



www.degruyter.com

Should you have **institutional access?** [Here's how to get it...](#)

Published since December 1, 1986

Journal of Basic and Clinical Physiology and Pharmacology

ISSN: 2191-0286

Editor-in-chief: Ugo Oliviero

Managing Editor: Alberto Marra

[OVERVIEW](#) [LATEST ISSUE](#) [ISSUES](#) [RANKING](#) [SUBMIT](#) **[EDITORIAL](#)**

Editorial

Editor-in-Chief:

Ugo Oliviero (Federico II University, Naples, Italy)

Deputy Editor:

Alberto M. Marra (Federico II University, Naples, Italy and University of Heidelberg, Germany)

Associate/Section Editors:

Emergency Medicine: Giorgio Bosso (S. Maria delle Grazie Hospital, Pozzuoli, Naples)*Oncology:* Evelyne Bischof (prev. Ewelina Biskup; University Hospital Basel, Switzerland, Shanghai University of Medicine & Health Sciences, Shanghai, China)*Hematology and Coagulation disorders:* Pablo Demelo-Rodríguez (G. Marangon Hospital and Universidad Complutense de Madrid, Spain)*Vascular Medicine:* Antonio Valvano (Legnano Hospital, Legnano, Italy)*Gastroenterology:* Theodor Voiosu (University of Bucharest, Bucharest, Romania)*Liver Disease:* Andrei Voiosu (University of Bucharest, Bucharest, Romania)*Neurology and Cerebrovascular:* Lorenzo Falsetti (Azienda Ospedaliero-Universitaria "Ospedali Riuniti" di Ancona, Italy)*Gender Medicine:* Valeria Raparelli (University of Ferrara, Ferrara, Italy)*Endocrinology:* Ieva Ruza, (University of Riga, Riga, Latvia)*Diabetology and Metabolism:* Mariarosaria De Luca (Federico II University, Naples)*Cardiovascular Diseases:* Andrea Salzano (Glenfield General Hospital, University of Leicester, Leicester, UK)*Heart Failure:* Antonio Cittadini (Federico II University of Naples, Naples, Italy)*Respiratory Medicine:* Salvatore Torrisi (University of Catania, Catania, Italy)*Geriatrics:* Leonardo Bencivenga (Federico II University, Naples, Italy)*Immunology:* Gilda Varricchi (Federico II University, Naples, Italy)*Rheumatology:* Domenico Sambataro (Artroreuma, Catania, Italy)*Basic Science:* Raffaella Spina (University of Maryland, School of Medicine, Baltimore, USA), Francesca Vinchi (New York Blood center, New York, USA), Roberta D'Assante (Federico II, Naples), Jia Liu (University of Virginia Health System, Charlottesville, USA)

Editorial Office:

E-mail: jbcpp.editorial@degruyter.com

(Deutsch)

If you have institutional access, your institution may have a subscription to this journal. **Authenticate with your institution** to access content.

— or —

Subscription

Electronic Individual
Electronic Institution**99,00 €**
641,00 €*To subscribe*[Contact our sales team](#)

Online ISSN: 2191-0286

Type: Journal

Language: English

Publisher: De Gruyter

First published: December 1, 1986

Publication Frequency: 6 Issues per Year

Audience: researchers and health professionals in the field of clinical physiology and pharmacology

Search journal



Subjects

[Architecture and Design](#)

[Arts](#)

[Asian and Pacific Studies](#)

[Business and Economics](#)

[Chemistry](#)

[Classical and Ancient Near Eastern Studies](#)

[Computer Sciences](#)

[Cultural Studies](#)

[Engineering](#)

[General Interest](#)

[Geosciences](#)

[History](#)

[Industrial Chemistry](#)

[Islamic and Middle Eastern Studies](#)

[Jewish Studies](#)

[Law](#)

[Library and Information Science, Book Studies](#)

[Life Sciences](#)

[Linguistics and Semiotics](#)

[Literary Studies](#)

[Material Sciences](#)

[Mathematics](#)

[Medicine](#)

[Music](#)

[Pharmacy](#)

[Philosophy](#)

[Physics](#)

[Social Sciences](#)

[Sports and Recreation](#)

[Theology and Religion](#)

Services

[For journal authors](#)

[For book authors](#)

[For librarians](#)

[Rights & Permissions](#)

Publications

[Publication types](#)

[Open Access](#)

About

[Contact](#)

[Career](#)

[About De Gruyter](#)

[Partnerships](#)

[Press](#)

[New website FAQs](#)

[Help/FAQ](#)

[Privacy policy](#)

[Accessibility](#)

[Terms & Conditions](#)

[Legal Notice](#)



© Walter de Gruyter GmbH 2022

Should you have institutional access? Here's how to get it...



Published by De Gruyter

Volume 32 Issue 4 - INTERNATIONAL CONFERENCE OF PHARMACY AND HEALTH SCIENCES: The 3rd JOINT CONFERENCE UNAIR - USM; Guest Editors: Suciati & Andang Miatmoko

July 2021

Issue of [Journal of Basic and Clinical Physiology and Pharmacology](#)[CONTENTS](#)[JOURNAL OVERVIEW](#)

🔒 Accessible June 25, 2021

Frontmatter

Page range: i-ii

[Cite this](#) [Download PDF](#)

Original Articles

🔒 Requires Authentication June 25, 2021

Cost of illness of diabetes mellitus in Indonesia: a systematic review

Yohana Febriani Putri Peu Patty, Mufarrihah, Yunita Nita

Page range: 285-295

[More](#) [Cite this](#)

🔒 Requires Authentication June 25, 2021

Social media health interventions to improve diabetes mellitus patient outcome: a systematic review

Riza Alfian, Umi Athiyah, Yunita Nita

Page range: 297-304

[More](#) [Cite this](#)

🔒 Requires Authentication June 25, 2021

Developing pharmacokinetics-pharmacodynamics model of valproic acid syrup based on prediction of population pharmacokinetics parameter and seizure frequency in Indonesian pediatric epilepsy outpatients

I Komang Prawira Nata Nugraha, Anita Purnamayanti, I Gusti Ngurah Made Suwarba, Nani Parfati

Page range: 305-311

[More](#) [Cite this](#)

🔒 Requires Authentication June 25, 2021

Acetylcholinesterase inhibitory activity of extract and fractions from the root of *Rauvolfia serpentina*(L.) Bth.ex Kurz

Suciati, Debora Poerwantoro, Aty Widyawaruyanti, Kornkanok Ingkaninan

Page range: 313-317

[More](#) [Cite this](#)

🔒 Requires Authentication June 25, 2021

Green tea and its active compound epigallocatechin-3-gallate (EGCG) inhibit neuronal apoptosis in a middle cerebral artery occlusion (MCAO) model

Abdulloh Machin, Imam Susilo, Djoko A. Purwanto

Page range: 319-325

[More](#) [Cite this](#)

🔒 Requires Authentication June 25, 2021

The effects of quercetin on nicotine-induced reward effects in mice

Mahardian Rahmadi, Dian Suasana, Silvy Restuning Lailis, Dinda Monika Nusantara Ratri, Chrismawan Ardianto

Page range: 327-333

[More](#) [Cite this](#)

🔒 Requires Authentication June 25, 2021

Resveratrol ameliorates physical and psychological stress-induced depressive-like behavior

Chrismawan Ardianto, Aniek Setiya Budiatin, I Nengah Budi Sumartha, Nurrahmi Nurrahmi, Mahardian Rahmadi, Junaidi Khotib

Page range: 335-340

[More](#) [Cite this](#)

🔒 Requires Authentication June 25, 2021

Translation and cross-cultural adaption of an instrument measuring patient's well-being under treatment for schizophrenia

Julaeha Julaeha, Umi Athiyah, Margarita Maria Maramis, Agus Sugianto, Andi Hermansyah

Page range: 341-347

More ▾ Cite this

Requires Authentication June 25, 2021

Quercetin promotes behavioral recovery and biomolecular changes of melanocortin-4 receptor in mice with ischemic stroke

Tuhfatul Ulya, Chrismawan Ardianto, Putri Anggreini, Aniek Setiya Budiati, Dwi Setyawan, Junaidi Khotib

Page range: 349-355

More ▾ Cite this

Requires Authentication June 25, 2021

Knowledge and attitudes of healthcare professionals on prescribing errors

Desak Ketut Ernawati, Ida Ayu Alit Widhiartini, Endang Budiarti

Page range: 357-362

More ▾ Cite this

Requires Authentication June 25, 2021

Inhibition of Ras and STAT3 activity of 4-(tert-butyl)-N-carbamoylbenzamide as antiproliferative agent in HER2-expressing breast cancer cells

Aguslina Kirtishanti, Siswandono Siswodihardjo, I Ketut Sudiana, Desak G. A. Suprabawati, Aristika Dinartyanti

Page range: 363-371

More ▾ Cite this

Requires Authentication June 25, 2021

Predicting the molecular mechanism of glucosamine in accelerating bone defect repair by stimulating osteogenic proteins

Marla Apriliani Gani, Ahmad Dzulfikri Nurhan, Aniek Setiya Budiati, Siswandono Siswodihardjo, Junaidi Khotib

Page range: 373-377

More ▾ Cite this

Requires Authentication June 25, 2021

Larvicidal toxicity and parasporal inclusion of native *Bacillus thuringiensis* BK5.2 against *Aedes aegypti*

Salamun, Fatimah, Ahmad Fauzi, Seling N. Praduwana, Ni'matuzahroh

Page range: 379-384

More ▾ Cite this

Requires Authentication June 25, 2021

Synthesis, ADMET predictions, molecular docking studies, and *in-vitro* anticancer activity of some benzoxazines against A549 human lung cancer cells

Melanny Ika Sulistyowaty, Retno Widyowati, Galih Satrio Putra, Tutuk Budiati, Katsuyoshi Matsunami

Page range: 385-392

More ▾ Cite this

Requires Authentication June 25, 2021

Thymoquinone and its derivatives against breast cancer with HER2 positive: *in silico* studies of ADMET, docking and QSPR

Adinda Adelia Wulandari, Achmad Aziz Choiri, Fitri, Tri Widiandani

Page range: 393-401

More ▾ Cite this

Requires Authentication June 25, 2021

Assessment of patient understanding of their conventional cardiac medicines and herbal prepared/derived products: preliminary survey and interviews with selected community-dwelling elderly patients in the Philippines

Jay P. Jazul, Trisha Michaela G. Arciga, Mary Angelie C. Ante, Danavin Gwyneth B. Berlin, Loise Françoise L. Ravana, Samantha A. Reyes, Jashanjit Singh

Page range: 403-413

More ▾ Cite this

Requires Authentication June 25, 2021

The development and validation of the health belief model questionnaire for measuring factors affecting adherence in the elderly with hypertension

Rodhiyatul Fithri, Umi Athiyah, Elida Zairina

Page range: 415-419

More ▾ Cite this

Requires Authentication June 25, 2021

Analysis of the side effect of QTc interval prolongation in the bedaquiline regimen in drug resistant tuberculosis patients

Denny Ardianto, Suharjono, Soedarsono, Umi Fatmawati

Page range: 421-427

More ▾ Cite this

Requires Authentication June 25, 2021

Shallot skin profiling, computational evaluation of physicochemical properties, ADMET, and molecular docking of its components

against P2Y12 receptor*Juni Ekowati, Kholidah Febriani, Itsna N. A. Yaqin, Adinda A. Wulandari, Indra H. Mulya, Kholis A. Nofianti, Achmad Syahrani*

Page range: 429-437

[More](#) [Cite this](#) Requires Authentication June 25, 2021**Analysis of HMGB-1 level before and after providing atorvastatin standard therapy in coronary artery disease patients with type-2 diabetes mellitus compared to without type-2 diabetes mellitus***Widya Handayani, Suharjono, Mohammad Yogiarto*

Page range: 439-446

[More](#) [Cite this](#) Requires Authentication June 25, 2021**Analysis of matrix metalloproteinase-9 levels among acute heart failure patients with ACE inhibitor therapy (Dr. Soetomo Regional General Hospital, Surabaya)***Ira Purbosari, Bambang Zubakti Zulkarnain, Muh Aminuddin, Umi Fatmawati*

Page range: 447-451

[More](#) [Cite this](#) Requires Authentication June 25, 2021**The correlation between self-related adherence, asthma-related quality of life and control of asthma in adult patients***Elida Zairina, Gesnita Nugraheni, Gusti Noorizka Veronika Achmad, Arie Sullistyarni, Yunita Nita, Arlef Bakhtiar, Muhammad Amin*

Page range: 453-458

[More](#) [Cite this](#) Requires Authentication June 25, 2021**Providing counseling through home pharmacy care (HPC) for hemodialysis patients with hypertension in lowering blood pressure***Rahmiyati Daud, Bambang Subakti Zulkarnain, Ivan Virnanda Amu*

Page range: 459-465

[More](#) [Cite this](#) Requires Authentication June 25, 2021**Community knowledge and attitude in recognizing asthma symptoms and using medication for asthma attacks: a cross-sectional study***Arina Dery Puspitasari, Bindaria Mutmaina Prabawati, Alfian Nur Rosyid*

Page range: 467-472

[More](#) [Cite this](#) Requires Authentication June 25, 2021**A study of anticoagulant therapy in patients with coronary artery disease***Arina D. Puspitasari, Daniel Dwi Christiananta Salean, Didik Hasmono, Rudy Hartono, Meity Ardiana*

Page range: 473-478

[More](#) [Cite this](#) Requires Authentication June 25, 2021**The association of FKBP5 polymorphism with asthma susceptibility in asthmatic patients***Sura F. Alsaifan, Haider Abdulhameed Alqaraghuli, Jabbar H. Yenzeei, Haider F. Ghazi*

Page range: 479-484

[More](#) [Cite this](#) Requires Authentication June 25, 2021**Gastroprotective effect of fluvoxamine and ondansetron on stress-induced gastric ulcers in mice***Mahardian Rahmadi, Nily Su'aida, Pratiwi Yustisari, Wahyu Agung Dewaandika, Elma Oktavia Hanaratri, Mareta Rindang Andarsari, Sumarno, Toetik Aryani*

Page range: 485-490

[More](#) [Cite this](#) Requires Authentication June 25, 2021**Osteoblast iron genes: real time PCR and microarray hybridization approach under hyperoxia***Prihartini Widiyanti, Hartmut Kuehn, Soetjipto Soetjipto*

Page range: 491-496

[More](#) [Cite this](#) Requires Authentication June 25, 2021**Attenuation of hyperplasia in lung parenchymal and colonic epithelial cells in DMBA-induced cancer by administering *Andrographis paniculata* Nees extract using animal model***Aniek Setiya Budiati, Ilham Bagus Sagitaras, Ika Putri Nurhayati, Nismatun Khairah, Khoirotin Nisak, Imam Susilo, Junaidi Khotib*

Page range: 497-504

[More](#) [Cite this](#) Requires Authentication June 25, 2021**N-nitrosodiethylamine induces inflammation of liver in mice**

Devy Maulidya Cahyani, Andang Miatmoko, Berlian Sarasitha Hariawan, Kusuma Eko Purwantari, Retno Sari

Page range: 505–510

More ▼ Cite this

Requires Authentication June 25, 2021

AST/ALT levels, MDA, and liver histopathology of *Echinometra mathaei* ethanol extract on paracetamol-induced hepatotoxicity in rats

Angelica Kresnamurti, Dita Nurlita Rakhma, Amatasari Damayanti, Septiyan Dwi Santoso, Enggar Restryarto, Wifqi Hadinata, Iwan Sahrial Hamid

Page range: 511–516

More ▼ Cite this

Requires Authentication June 25, 2021

Development, characterization, molecular docking, and *in vivo* skin penetration of coenzyme Q10 nanostructured lipid carriers using tristearin and stearyl alcohol for dermal delivery

Ni Luh Dewi Aryani, Siswandono Siswodihardjo, Widji Soetratri, Nadia Fitria Indah Sari

Page range: 517–525

More ▼ Cite this

Requires Authentication June 25, 2021

The effect of *Camellia sinensis* (green tea) with its active compound EGCG on neuronal cell necroptosis in *Rattus norvegicus* middle cerebral artery occlusion (MCAO) model

Abdulloh Machin, Ramidha Syaharani, Imam Susilo, Muhammad Hamdan, Dyah Fauziah, Djoko Agus Purwanto

Page range: 527–531

More ▼ Cite this

Requires Authentication June 25, 2021

Hepatoprotective effect of ethanolic extract of sugarcane (*Saccharum officinarum* Linn.) leaves

Ika P. Dewi, Rifdah B. Kwintana, Jihan U. Ulinnuha, Fadhillah Rachman, Fransiska M. Christianty, Diana Holiday

Page range: 533–540

More ▼ Cite this

Requires Authentication June 25, 2021

Correlation between the exposure time to mobile devices and the prevalence of evaporative dry eyes as one of the symptoms of computer vision syndrome among Senior High School students in East Java, Indonesia

Rozalina Loebis, Bambang Subakti Zulkarnaïn, Nadhifa Zahra

Page range: 541–545

More ▼ Cite this

Requires Authentication June 25, 2021

The effect of various high-fat diet on liver histology in the development of NAFLD models in mice

Mahardian Rahmadi, Ahmad Dzulfikri Nurhan, Eka Dewi Pratiwi, Devita Ardina Prameswari, Sisca Melani Panggono, Khoirotin Nisak, Junaidi Khotib

Page range: 547–553

More ▼ Cite this

Requires Authentication June 25, 2021

Fabrication and characterization of bovine hydroxyapatite-gelatin-alendronate scaffold cross-linked by glutaraldehyde for bone regeneration

Samirah, Aniek Setiya Budiati, Ferdiansyah Mahyudin, Jumaidi Khotib

Page range: 555–560

More ▼ Cite this

Requires Authentication June 25, 2021

Health related quality of life among postmenopausal woman with hormone responsive HER2- breast cancer in Indonesia

Ria Etikasari, Tri Murti Andayani, Dwi Endarti, Kartika Widayati Taroeno-Hariadi

Page range: 561–565

More ▼ Cite this

Requires Authentication June 25, 2021

Gender differences in the blood glucose type 2 diabetes patients with combination rapid and long acting insulin therapy

Dinda M. N. Ratri, Arina D. Puspitasari, Cahyo W. Nugroho, Budi Suprpti, Suharjono, Christoper P. Alderman

Page range: 567–570

More ▼ Cite this

Requires Authentication June 25, 2021

Correlation of dietary iron intake and serum iron with thyroid stimulating hormone (TSH) and free thyroxine (FT4) levels in adult hyperthyroid patients

Utami Harjantini, Yulia Lanti Retno Dewi, Diffah Hanim, Ida Nurwati

Page range: 571–576

More ▼ Cite this

Requires Authentication June 25, 2021

The effect of pillbox use and education by pharmacist toward medication adherence in diabetes mellitus patients in a Primary Health Care Center in Mataram*Mahacita Andanafusia, Yunita Nita, Umi Athiyah*

Page range: 577-582

[More](#) [Cite this](#)[Requires Authentication](#) June 25, 2021**Variation concentration effect of propyleneglycol, glycerin, and polyethyleneglycol 400 to physical properties and dissolution rate of loratadine liquisolid tablet***Milhanika Christiningtyas Eryani, Esti Hendradi, Siswandono*

Page range: 583-587

[More](#) [Cite this](#)[Requires Authentication](#) June 25, 2021**Role of *Centella asiatica* and ceramide in skin barrier improvement: a double blind clinical trial of Indonesian batik workers***Sylvia Anggraeni, Menul Ayu Umbarowati, Damayanti Damayanti, Anang Endaryanto, Cita Rosita Sigit Prakoeswa*

Page range: 589-593

[More](#) [Cite this](#)[Requires Authentication](#) June 25, 2021**Secondary metabolite and antipyretic effects of *Maja (Crescentia cujete L.)* in fever-induced mice***Teodhora, Munawarohthus Sholikha, Asniatul Ania, Ika Mariya Kusuma*

Page range: 595-601

[More](#) [Cite this](#)[Requires Authentication](#) June 25, 2021**Hydration effect on kidney function and serum electrolyte in children with tumor lysis syndrome (TLS) and risk of TLS***Yulistiani, Claudia Tiffany, I. Dewa Gede Ugrasena, Mariyatul Qibtiyah*

Page range: 603-609

[More](#) [Cite this](#)[Requires Authentication](#) June 25, 2021**Drug utilization study and cost analysis of adult β -thalassemia major patient therapy at Dr. Soetomo General Hospital Surabaya***Hasna Qatrunnada, Suharjo, Siprianus Ugraseno Yudho Bintoro, Siti Wahyuni*

Page range: 611-616

[More](#) [Cite this](#)[Requires Authentication](#) June 25, 2021**The role of hyperbaric oxygen to platelet aggregation in noninsulin-dependent diabetes mellitus (NIDDM)***Prihartini Widiyanti, Purnomo Suryohudoyo*

Page range: 617-621

[More](#) [Cite this](#)[Requires Authentication](#) June 25, 2021**Cocrystal formation of loratadine-succinic acid and its improved solubility***Dwi Setyawan, Firdaus Rendra Adyaksa, Hanny Lystia Sari, Djajeng Putri Paramita, Retno Sari*

Page range: 623-630

[More](#) [Cite this](#)[Requires Authentication](#) June 25, 2021**The role of chondroitin sulfate to bone healing indicators and compressive strength***Herry Wibowo, Prihartini Widiyanti, Syaifullah Asmiragani*

Page range: 631-635

[More](#) [Cite this](#)[Requires Authentication](#) June 25, 2021**The effects of quercetin on the expression of SREBP-1c mRNA in high-fat diet-induced NAFLD in mice***Jamal Nasser Saleh Al-maamari, Mahardian Rahmadi, Sisca Melani Panggono, Devita Ardina Prameswari, Eka Dewi Pratiwi, Christmawan Ardianto, Santhra Segaran Balan, Budi Suprapti*

Page range: 637-644

[More](#) [Cite this](#)[Requires Authentication](#) June 25, 2021**Analysis of stress ulcer prophylaxis drug regimentation in surgical patients***Dhani Wijaya, Suharjo, Fendy Matulatan, Elfri Padolo*

Page range: 645-649

[More](#) [Cite this](#)[Requires Authentication](#) June 25, 2021**The stability and irritability study of the chitosan-*Aloe vera* spray gel as wound healing**

Dini Retnowati, Retno Sari, Esti Hendradi, Septiani Septiani

Page range: 651-656

More ▾ Cite this

Requires Authentication June 25, 2021

Effectiveness of citicoline in pediatric patients with refractive amblyopia in Surabaya, East Java, Indonesia

Rozalina Loebis, Bambang Subakti Zulkarnain, Fitri Amalia Siswanto

Page range: 657-661

More ▾ Cite this

Requires Authentication June 25, 2021

The thermodynamic study of *p*-methoxycinnamic acid inclusion complex formation, using β -cyclodextrin and hydroxypropyl- β -cyclodextrin

Dewi Isadiartuti, Noonna Rosita, Jumi Ekowati, Achmad Syahrani, Toetik Ariyani, M. Ainur Rifqi

Page range: 663-667

More ▾ Cite this

Requires Authentication June 25, 2021

The effect of chitosan type and drug-chitosan ratio on physical characteristics and release profile of ketoprofen microparticles prepared by spray drying

Muhammad A. S. Rijal, Hanah Masitah, Fanny Purvitasari, Retno Sari

Page range: 669-673

More ▾ Cite this

Requires Authentication June 25, 2021

The maximum dose and duration in the therapy single use methotrexate to achieve remission by rheumatoid arthritis patients through disease activity score 28 (DAS28)

Anisyah Achmad, Tiika Yasmin Rahmayanti, Bagus Putu Putra Suryana

Page range: 675-680

More ▾ Cite this

Accessible June 25, 2021

Knowledge, attitudes, and practices (KAP) towards COVID-19 among university students in Pakistan: a cross-sectional study

Shah Faisal, Junaidi Khotib, Elida Zairina

Page range: 681-686

More ▾ Cite this Download PDF

Requires Authentication June 25, 2021

The impact of glutaraldehyde on the characteristics of bovine hydroxyapatite-gelatin based bone scaffold as gentamicin delivery system

Aniek Setiyo Budiadin, Maria Apriliani Gani, Chrismawan Ardianto, Samirah, Sahrati Yudiapriyah Daeng Pattah, Fitroh Mubarakah, Junaidi Khotib

Page range: 687-691

More ▾ Cite this

Requires Authentication June 25, 2021

Analysis of the use of antibiotics profile and factors of surgical site infections study on digestive and oncology surgeries

Lisa Narulita, Suharjo, Kuntaman, Mohammad Alqram

Page range: 693-700

More ▾ Cite this

Requires Authentication June 25, 2021

Second internal transcribed spacer (ITS-2) as genetic marker for molecular characterization of *Sarcoptes scabiei* in rabbits from several areas of East Java, Indonesia

Nunuk Dyah Retno Lastuti, Nur Rusdiana, Poedji Hastuti

Page range: 701-705

More ▾ Cite this

Requires Authentication June 25, 2021

Design of gossypetin derivatives based on naturally occurring flavonoid in *Hibiscus sabdariffa* and the molecular docking as antibacterial agents

Nuzul W. Diyah, Isnaeni, Shabrina W. Hidayati, Bambang T. Purwanto, Siswandono

Page range: 707-714

More ▾ Cite this

Requires Authentication June 25, 2021

Discovery of new targeting agents against GAPDH receptor for antituberculosis drug delivery

Muhammad Amirul Asyraf Noh, Siti Sarah Fazalul Rahiman, Habibah A Wahab, Amirah Mohd Gazzali

Page range: 715-722

More ▾ Cite this

Requires Authentication June 25, 2021

The effect of red passion fruit (*Passiflora edulis* Sims.) fermentation time on its activity against Extended Strain Methicillin-Resistant (ESBL) *Escherichia coli* and Methicillin-Resistant *Staphylococcus aureus* (MRSA)

Iif Hanifa Nurrosyidah, Ni Made Mertaniasih, Isnaeni

Page range: 723-727

[More](#) [Cite this](#)[Requires Authentication](#) June 25, 2021**Antibiotic use on acute respiratory tract infection nonpneumonia and nonspecific diarrhea in Primary Health Care Centre in Banjarbaru City, South Kalimantan, Indonesia**

Rizky Liestya Wardani, Suharjo, Kuntaman, Agus Widjaja

Page range: 729-735

[More](#) [Cite this](#)[Requires Authentication](#) June 25, 2021**Screening of anti-HIV activities in ethanol extract and fractions from *Ficus fistulosa* leaves**

Siti Qamariyah Khairunisa, Dwi Wahyu Indriati, Lidya Tumewu, Aty Widyawaruyanti, Nasronudin Nasronudin

Page range: 737-742

[More](#) [Cite this](#)[Requires Authentication](#) June 25, 2021**The characteristics of lactic acid bacteria isolated from fermented food as potential probiotics**

Victoria Yulita Fitriani, Budi Suprapti, Muhammad Amin

Page range: 743-749

[More](#) [Cite this](#)[Requires Authentication](#) June 25, 2021**Profile of *gyrA* gene mutation in clinical isolate of levofloxacin resistant *Escherichia coli***

Alifia Risma Fahmi, Suharjo, Kuntaman

Page range: 751-754

[More](#) [Cite this](#)[Requires Authentication](#) June 25, 2021**Antimicrobial activity of *Centella asiatica* and *Gigantochloa apus***

Siti Mudallana

Page range: 755-759

[More](#) [Cite this](#)[Requires Authentication](#) June 25, 2021**Drug-related problems of antibiotic use in gastroenteritis related to patient therapy outcomes at Universitas Gadjah Mada Hospital**

Fivy Kurniawati, Nanang Munif Yasin, Farida Aulia, Gidrie Vinanda Krishna

Page range: 761-766

[More](#) [Cite this](#)[Requires Authentication](#) June 25, 2021**The impact of suitability of empirical antibiotics use on therapeutic outcome of respiratory tract infection patients at inpatient wards of Universitas Gadjah Mada Academic Hospital**

Fivy Kurniawati, Nanang Munif Yasin, Safina Nur Azizah, Silvia Ayu Purbaningtyas

Page range: 767-771

[More](#) [Cite this](#)[Requires Authentication](#) June 25, 2021**Genetic profile mutation *rpoB* in clinical isolate of rifampicin-resistant *Staphylococcus aureus***

Risa Zulfiana, Suharjo, Kuntaman

Page range: 773-776

[More](#) [Cite this](#)[Requires Authentication](#) June 25, 2021**Hematological side effect analysis of linezolid in MDR-TB patients with individual therapy**

Novan Yusuf Indra Pratama, Bambang Subakti Zulkarnain, Soedarsono, Umi Fatmawati

Page range: 777-781

[More](#) [Cite this](#)[Requires Authentication](#) June 25, 2021**Adverse drug reaction and its management in tuberculosis patients with multidrug resistance: a retrospective study**

Wenny Putri Nilamsari, Muhammad Fajar Rizqi, Natasya Olga Regina, Prastuti Asta Wulaningrum, Umi Fatmawati

Page range: 783-787

[More](#) [Cite this](#)[Requires Authentication](#) June 25, 2021**Analysis of prophylactic antibiotic use and risk factor of postoperative infection in urological surgery patients**

Ratri Rokhani, Suharjono, Kuntaman, Mohammad Akram

Page range: 789-794

More ▾ Cite this

Requires Authentication June 25, 2021

Molecular docking studies of *Nigella sativa* L and *Curcuma xanthorrhiza* Roxb secondary metabolites against histamine N-methyltransferase with their ADMET prediction

Ahmad Dzulfikri Nurhan, Maria Apriliani Gani, Aniek Setiya Budiati, Siswandono Siswodihardjo, Junaidi Khotib

Page range: 795-802

More ▾ Cite this

Requires Authentication June 25, 2021

Prediction of compounds with antiosteoporosis activity in *Chrysophyllum cainito* L. leaves through *in silico* approach

Burhan Ma'arif, Hilwa Fitri, Nisfatul Lailatus Saidah, Luqman Alfani Najib, Achmad Hamdan Yuwafi, Ria Ramadhani Dwi Atmaja, Fidla Rizkiah Inayatillah, Meilina Ratna Dianti, Hening Laswati, Mangestuti Agil

Page range: 803-808

More ▾ Cite this

Requires Authentication June 25, 2021

Phyllanthin and hypophyllanthin, the isolated compounds of *Phyllanthus niruri* inhibit protein receptor of corona virus (COVID-19) through *in silico* approach

Honey Dzikri Marhaeny, Aty Widyawaruyanti, Tri Widiandani, Achmad Fuad Hafid, Tutik Sri Wahyuni

Page range: 809-815

More ▾ Cite this

Requires Authentication June 25, 2021

***Cratogeomys sumatranum* stem bark exhibited antimalarial activity by Lactate Dehydrogenase (LDH) assay**

Lidya Tumewu, Fendi Yoga Wardana, Hilkatul Ilmi, Adita Ayu Permanasari, Achmad Fuad Hafid, Aty Widyawaruyanti

Page range: 817-822

More ▾ Cite this

Requires Authentication June 25, 2021

Endophytic fungi inhabiting *Physalis angulata* L. plant: diversity, antioxidant, and antibacterial activities of their ethyl acetate extracts

Kartika Dyah Pahupi, Muhammad Ilyas, Andria Augusta

Page range: 823-829

More ▾ Cite this

Requires Authentication June 25, 2021

Exploration of several plants from Baung Forest on bone formation cell models

Retno Widyawati, Neny Purwitasari, Rice Disi Oktarina, Wiwied Ekasari, Saarah Khairunnisa, Hsin-I. Chang

Page range: 831-837

More ▾ Cite this

Requires Authentication June 25, 2021

***In vitro* antimalarial activity of *Garcinia parvifolia* Miq. Stem extracts and fractions on *Plasmodium falciparum* lactate dehydrogenase (LDH) assay**

Marsih Wijayanti, Hilkatul Ilmi, Einstenia Kemalahayati, Lidya Tumewu, Fendi Yoga Wardana, Suciati, Achmad Fuad Hafid, Aty Widyawaruyanti

Page range: 839-844

More ▾ Cite this

Requires Authentication June 25, 2021

Antioxidant and antiviral potency of *Begonia medicinalis* fractions

Muhammad Sulaiman Zubair, Siti Qamariyah Khairunnisa, Evi Sulastri, Ihwan, Agustinus Widodo, Nasronudin, Ramadanil Pitopang

Page range: 845-851

More ▾ Cite this

Requires Authentication June 25, 2021

Artocarpus sericarpus* stem bark contains antimalarial substances against *Plasmodium falciparum

Lidya Tumewu, Lutfah Qurrota A'yun, Hilkatul Ilmi, Achmad Fuad Hafid, Aty Widyawaruyanti

Page range: 853-858

More ▾ Cite this

Requires Authentication June 25, 2021

Formulation and characterization of *Eleutherine palmifolia* extract-loaded self-nanoemulsifying drug delivery system (SNEDDS)

Rahmi Annisa, Mochammad Yuwono, Esti Hendradi

Page range: 859-865

More ▾ Cite this

Requires Authentication June 25, 2021

Analytical method for the determination of curcumin entrapped in polymeric micellar powder using HPLC

Helmy Yusuf, Nina Wijiani, Rizka Arifa Rahmawati, Rieta Primaharinastiti, M. Agus Syamsur Rijal, Dewi Isadiartuti

Page range: 867-873

More ▾ Cite this

Requires Authentication June 25, 2021

Challenges in the provision of natural medicines by community pharmacists in East Java Province, Indonesia

Hanni P. Puspitasari, Dhita Fatmaningrum, Sa'adatus Zahro, Shofi Salsabila, Zulfia A. Rizqulloh, Ana Yuda, Mufarrihah, Anila I. Sukorini, Neny Purwitasari

Page range: 875-880

More ▾ Cite this

Requires Authentication June 25, 2021

In vitro and in silico analysis of phytochemical compounds of 96% ethanol extract of semanggi (*Marsilea crenata* Presl.) leaves as a bone formation agent

Agnis P.R. Aditama, Burhan Ma'arif, Hening Laswati, Mangestuti Agil

Page range: 881-887

More ▾ Cite this

Requires Authentication June 25, 2021

Inhibitory activity of *Urena lobata* leaf extract on alpha-amylase and alpha-glucosidase: in vitro and in silico approach

Yudi Purnomo, Juliah Makdasari, Faiqoh Inayah Fatahillah

Page range: 889-894

More ▾ Cite this

Case Report

Requires Authentication June 25, 2021

Effect of hydrocortisone on hypocortisolism caused by pituitary adenoma

Niswah N. Qonita, Hanik B. Hidayati

Page range: 895-898

More ▾ Cite this

Search Journal



This issue All issues

Subjects

Architecture and Design
Arts
Asian and Pacific Studies
Business and Economics
Chemistry
Classical and Ancient Near Eastern Studies
Computer Sciences
Cultural Studies
Engineering
General Interest

Geosciences
History
Industrial Chemistry
Islamic and Middle Eastern Studies
Jewish Studies
Law
Library and Information Science, Book Studies
Life Sciences
Linguistics and Semiotics
Literary Studies

Materials Sciences
Mathematics
Medicine
Music
Pharmacy
Philosophy
Physics
Social Sciences
Sports and Recreation
Theology and Religion

Services

For journal authors
For book authors
For librarians
Rights & Permissions

Publications

Publication types
Open Access

About

Contact
Career
About De Gruyter
Partnerships
Press
New website FAQs

[Help/FAQ](#)

[Privacy policy](#)

[Accessibility](#)

[Terms & Conditions](#)

[Legal Notice](#)



© Walter de Gruyter GmbH 2022

Abdulloh Machin*, Imam Susilo and Djoko A. Purwanto

Green tea and its active compound epigallocatechin-3-gallate (EGCG) inhibit neuronal apoptosis in a middle cerebral artery occlusion (MCAO) model

<https://doi.org/10.1515/jbcpp-2020-0454>

Received November 28, 2020; accepted February 20, 2021

Abstract

Objectives: To determine the effect of green tea with the active ingredient epigallocatechin-3-gallate (EGCG) on the inhibition of apoptosis in the middle cerebral artery occlusion (MCAO) model.

Methods: Four month old male *Rattus norvegicus* rats with a body weight of 200–275 g was used for the MCAO model and divided into five groups, and the treatment was carried out for 7 days. Before being sacrificed, the subject had 1 cc of blood drawn for high mobility group box 1 (HMGB-1) examination using enzyme-linked immunosorbent assay (ELISA), and after being sacrificed, the brain tissue specimen was taken to examine caspase-3 and B-cell lymphoma 3 (BCL-3) using immunohistochemistry methods.

Results: There was no significant difference in HMGB-1 results for the treatment group compared to the control group (P1: 384.20 ± 231.72 [$p = 0.553$]; P2: 379.11 ± 268.4 [$p = 0.526$]; P3: $284, 87 \pm 276.19$ [$p = 0.140$]; P4: 435.32 ± 279.95 [$p = 0.912$]). There is a significant increase in BCL-2 expression between the treatment group compared to the control group (P1: 2.58 ± 0.51 [$p = 0.04$]; P2: 3.36 ± 0.50 [$p < 0.001$]; P3: 4.00 ± 0.42 [$p < 0.001$]; P4: 3.60 ± 0.52 [$p < 0.001$]). There was a significant difference in caspase-3 expression compared to the control group in the P3 group (P1: 4.33 ± 0.49 [$p = 0.652$]; P2: 4.09 ± 0.30 [$p = 0.136$]; P3: 3.58 ± 0.51 [$p = 0.01$]; P4: 3.89 ± 0.42 [$p = 0.063$]). There is no correlation between HMGB-1 and caspase-3 ($r = -0.063$; $p = 0.613$) or BCL-2 ($r = -0.106$; $p = 0.396$). There is significant

negative correlation between caspase-3 and BCL-2 ($r = -0.459$; $p = 0.000$).

Conclusions: Green tea with the active ingredient EGCG can inhibit neuronal cell death through the apoptotic pathway and not through the activation of HMGB-1.

Keywords: BCL-2; Caspase-3; EGCG; green tea; HMGB-1; MCAO.

Introduction

There is a decrease in blood flow during ischemic stroke that causes a decrease in adenosine triphosphate (ATP) production and causes lactic acidosis and homeostatic ion imbalance [1–3]. Homeostatic ion imbalance will cause calcium influx that will trigger phospholipase and protease and will damage cell membrane and protein [4, 5]. An increase in intracellular calcium will also trigger reactive oxygen species on mitochondria that will cause damage [6, 7].

High mobility group box 1 (HMGB-1) is a nuclear factor protein and a stress marker in the cells [8–10]. Some studies show that HMGB-1 has capability as a proinflammatory mediator that triggers inflammation during ischemia or sepsis [11–13]. HMGB-1 also increases during a pathologic condition and hours after ischemic injuries such as myocardial infarction or ischemic neuronal injury and cell death [13]. Some studies show that the HMGB-1 level increases after ischemic stroke, myocardial infarction, and hemorrhagic shock; thus, it plays an important role in the pathogenesis of ischemic stroke [8, 9, 14].

Ischemic injury can cause apoptotic cell death, and apoptotic cell death also occurs in stroke. The key mediator of apoptotic cell death is caspase-3 [15, 16]. Caspase-3 is the most well-characterized effector caspase and will trigger apoptosis when it is activated by other caspases [17]. Caspase-3 as an effector caspase plays a crucial role during neuronal development and under pathological conditions in the brain tissue such as cerebral ischemia, intracerebral hemorrhage, and brain injury. Caspase-3 is the most abundant cysteine

*Corresponding author: **Abdulloh Machin**, Department Neurology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia, Phone: +62 813 3000 8306, E-mail: abdulloh.m@fk.unair.ac.id
Imam Susilo, Department Clinical Pathology, Faculty of Medicine, Universitas Airlangga, Surabaya, Indonesia
Djoko A. Purwanto, Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Universitas Airlangga, Surabaya, Indonesia

aspartate expressed in adult rodent brains; thus, a change in its expression is easier to monitor [2]. Asahi et al. reported in his study that during 1 h after ischemic stroke there is up-regulation of mRNA caspase-3 in the brain ischemic tissue that will increase caspase-3 expression. Namura et al. also detected caspase-3 and its product in mouse brain tissues during early reperfusion or 2 h after middle cerebral artery occlusion (MCAO) [16, 18, 19].

B-cell lymphoma 2 (BCL-2) was first identified in B-cell lymphoma, and it functions as a key regulator in the intrinsic apoptosis pathway in the mitochondria. BCL-2 also have function in the antiapoptotic pathway with B-cell lymphoma extra large (BCL-XL), myeloid cell leukemia 1 (MCL-1), and BCL-2-like protein 2 (BCL-2L2) with contour BCL-2 homology (BH) domain. BCL-2 is widely expressed during development in the brain including neuroepithelial cells and cerebral ventricle [20]. Study on primary neuronal cell culture and animal model shows that BCL-2 overexpression can protect neuronal damage and infarct size again N-methyl-D-aspartate (NMDA) induced excitotoxicity [21, 22]. Overexpression of BCL-2 also blocks apoptosis-inducing factor (AIF) and will improve cortical neuron survival after cerebral ischemia [22]. BCL-2 also acts as a key regulator of mitochondrial permeability and maintains mitochondria homeostasis. It is released in response to molecular-induced apoptosis and will prevent cell from apoptotic cell death. BCL-2 and BCL-XL protein are located in the mitochondria and endoplasmic reticulum. BCL-2 in the mitochondria maintains mitochondrial integrity and inhibits the release of proapoptotic molecule [20, 22, 23].

Green tea is the second most common drink in the world and has some beneficial effect because it has some polyphenol known as catechin and also has antioxidant property. Epigallocatechin-3-gallate (EGCG) is one of the green tea catechins and it makes up 63% of total catechin. EGCG is a potent antioxidant and a free-radical scavenger [24, 25]. Green tea can prevent neurodegenerative disease; a meta-analysis shows that people who drink more than three cups of tea a day have 21% less chance of having stroke than people who drink less than one cup a day [26]. Studies on animal models show that treatment using EGCG in an ischemic reperfusion brain tissue model decreases ischemic lesion [25, 27–29]. EGCG has free-radical scavenger function and can protect neuronal cell from oxidative damage induced by pro-oxidant agent [30]. Some animal studies show that EGCG increases mitochondrial function and decreases oxidative stress [31, 32]. Treatment with 30 mg/kg BW of EGCG can prevent isoproterenol-induced mitochondrial damage in the animal model [32].

Based on information above, green tea with its active compound EGCG may play an important role in cerebral neuroprotection because it has antioxidant and free-radical scavenger effect. It is important to conduct research to determine the effect of green tea treatment with its active compound EGCG on the level of HMGB-1 and expression of neuronal apoptosis marker in an MCAO model.

Materials and methods

We performed an MCAO model using male *Rattus norvegicus* rats obtained from Gajah Mada University's breeding center that have been published on Eurasia J Biosci 14, 1813–1820 (2020). We evaluated the HMGB-1 level using enzyme-linked immunosorbent assay (ELISA) methods (LS Bio). On the 7th day, we obtained blood for serum ELISA examination.

Immunohistochemistry examination

The brain tissue used is from a male *R. norvegicus* MCAO model and was obtained from the animal laboratory in the Faculty of Pharmacy, Universitas Airlangga. The tissue taken is the 1.5 cm area of the brain tissue in front of and behind the bregma and was then stored in paraffin blocks. The paraffin block was then cut as thick as 5 μ m, and the slice was placed on the slide and heated at 65°C for 2 h so that the tissue can stick to the microscopic slide. The microscopic slides were dipped in xylene three times for 5 min each to remove paraffin. The tissue was rehydrated by dipping in 100% ethanol, then 95% ethanol, and then in 70% ethanol; then the microscopic slides were removed from 70% alcohol and then soaked in Tris buffer for 1 h. Peroxide activity is then removed by dipping in a 3% peroxide solution for 3 min. The microscopic slides were cleaned from Tris buffer for 3 min and given a conjugate enzyme after administration of the body and dissolved in Tris buffer saline with 1% bovine saline albumin and incubated at room temperature for 1 h, then give chromogen for 10 min at room temperature and rinse with running water for 5 min. The microscopic slide was read according to the guidelines of DC Allred, MD, et al. [33] by means of scoring consisting of proportion score, with a score of 0 indicating no cells showed marker expression in all fields of view, a score of 1 when an expression of 0–1% was obtained in the field of view examined, a score of 2 when an expression of >1–10% was obtained in the field of view, a score of 3 when an expression of >10–33.3% was obtained, a score of 4 when an expression of >33.3–66.6% was obtained, and a score of 5 when a marker expression of >66.6–100% was obtained. Then, the intensity score is calculated, that is, a score of 0 if no restraint is obtained, a score of 1 if weakening is obtained, a score of 2 if moderate warming is obtained, and a score of 3 if strong warming is obtained. The final score is the proportion score added to the intensity score.

Statistical analysis

All variables were tested descriptively, and then, normality was tested using the Kolmogorov–Smirnov test. Differences in expression

between the two groups were analyzed using the Kruskal–Wallis test, followed by the Mann–Whitney test. Furthermore, all variables were tested for correlation using the Pearson or Spearman test. Then, all variables were analyzed using path analysis.

Results

We performed Immunohistochemical assessment for BCL-2 and caspase-3. We also performed ELISA for HMGB-1. There is a significant difference between all groups ($p > 0.01$), so we performed Kruskal–Wallis and Mann–Whitney tests to test the difference between groups (see Table 1).

Our data show that there is no significant difference between the control and intervention group with respect to the HMGB-1 level. According to our finding, neither EGCG nor green tea extract influenced the HMGB-1 level because of excessive release of HMGB-1 during acute ischemic stroke.

According to Table 2, the higher dose EGCG (30 mg/kg BW) and green tea extract (30 mg/kg BW) can suppress caspase-3 expression. This result shows that EGCG can inhibit apoptosis in the *R. norvegicus* MCAO model. There is a decrease in caspase-3 expression in the group treated with the lower dose of EGCG, but the decrease was not statistically significant. This result shows that inhibition of caspase-3 expression is dose dependent and significant inhibition of EGCG started at the dose of 30 mg/kg BW. Figure 1 shows expression of caspase-3 in neuronal cells after treatment with 30 mg/kg BW of EGCG.

According to Table 3, either EGCG or extract green tea can increase BCL-2 expression in the MCAO model. The intensity of expression of BCL-2 is dependent on dosage. Green tea extract also increases BCL-2 expression; the expression in the group treated with green tea extract is similar to that in the group treated with 30 mg/kg BW of EGCG. This result shows that either EGCG or green tea

Table 1: Mean difference of HMGB-1 between the groups shows that there is no significant difference between intervention groups compared to the stroke control group.

Group	Mean \pm SD	p-Value
P0 (n = 10)	1458.42 \pm 329.11	–
P1 (n = 12)	384.20 \pm 231.72	0.553
P2 (n = 11)	379.11 \pm 268.47	0.526
P3 (n = 12)	284.87 \pm 276.19	0.140
P4(n = 10)	435.32 \pm 279.95	0.912

SD = standard deviation; HMGB-1 = high mobility group box 1; EGCG = epigallocatechin-3-gallate; P0 = control group; P1 = group treated with 10 mg/kg BW of EGCG; P2 = group treated with 20 mg/kg BW of EGCG; P3 = group treated with 30 mg/kg BW of EGCG; P4 = group treated with 30 mg/kg BW of green tea extract.

Table 2: Mean difference of caspase-3 shows that there is the significant difference in caspase-3 expression in the group treated with 30 mg/kg BW of EGCG.

Group	Mean \pm SD	p-Value
P0 (n = 10)	4.40 \pm 0.70	–
P1 (n = 12)	4.33 \pm 0.49	0.652
P2 (n = 11)	4.09 \pm 0.30	0.136
P3 (n = 12)	3.58 \pm 0.51	0.010
P4(n = 10)	3.89 \pm 0.42	0.063

SD = standard deviation; EGCG = epigallocatechin-3-gallate; P0 = control group; P1 = group treated with 10 mg/kg BW of EGCG; P2 = group treated with 20 mg/kg BW of EGCG; P3 = group treated with 30 mg/kg BW of EGCG; P4 = group treated with 30 mg/kg BW of green tea extract. This result shows that only the higher dose of EGCG can suppress caspase-3 expression.




Figure 1: Caspase-3 expression in neuronal cell, shown in green arrow. There is increase in expression of caspase-3 expression (brown) in neuronal cells in the MCAO model. MCAO = middle cerebral artery occlusion.

extract can increase antiapoptotic activity and that this activity depends on the dose of EGCG. Green tea extract also can decrease apoptotic activity, and this activity is similar to that of its active compound EGCG. Figure 2 shows expression of BCL-2 in neuronal cells after treatment using 30 mg/kg BW of EGCG.

According to Table 4, there is negative correlation between HMGB-1 and caspase-3, but is not statistically significant ($r = -0.063$; $p = 0.613$), and there is no statistically significant and negative correlation between HMGB-1 and caspase-3 ($r = -0.106$; $p = 0.396$). There is also significant negative correlation between BCL-2 and caspase-3 ($p = -0.459$; $p = 0.000$). These data show that the HMGB-1 level did not influence the expression of either caspase-3 or BCL-2. Correlation between caspase-3 and BCL-2 shows that EGCG can decrease caspase-3 expression and increase BCL-2 expression or in another

Table 3: Mean difference of BCL-2 expression between the groups shows that there is increase in BCL-2 expression in intervention groups compared to the control group.

Group	Mean \pm SD	p-Value
P0 (n = 10)	1.80 \pm 1.03	–
P1 (n = 12)	2.58 \pm 0.51	0.040
P2 (n = 11)	3.36 \pm 0.50	0.001
P3 (n = 12)	4.00 \pm 0.42	0.001
P4 (n = 10)	3.60 \pm 0.52	0.001

SD = standard deviation; BCL-2 = B-cell lymphoma 2; EGCG = epigallocatechin-3-gallate; P0 = control group; P1 = group treated with 10 mg/kg BW of EGCG; P2 = group treated with 20 mg/kg BW of EGCG; P3 = group treated with 30 mg/kg BW of EGCG; P4 = group treated with 30 mg/kg BW of green tea extract. There is significant difference between the control group and the sham group.




Figure 2: Expression of BCL-2 in neuronal cells is shown in green arrow. There is increase in BCL-2 expression in neuronal cells (brown). BCL-2 = B-cell lymphoma 2.

Table 4: Correlation between variables.

Variable 1	Variable 2	r	p-Value
HMGB-1	Caspase-3	–0.063	0.613
Caspase-3	BCL-2	–0.459	0.000
BCL-2	HMGB-1	–0.106	0.396

BCL-2 = B-cell lymphoma 2; HMGB-1 = high mobility group box 1. There is significant negative correlation between expression of caspase-3 and BCL-2, but there is no significant correlation between HMGB-1 and caspase-3 expression or between BCL-2 and HMGB-1 expression.

word EGCG can protect neuronal cells from apoptosis through decreasing proapoptotic protein expression and increasing antiapoptotic protein expression.

Discussion

Our study shows no difference in the HMGB-1 level between the intervention group and control group, and in another

way, it shows that neither green tea extract nor EGCG, as its active compound, influenced the HMGB-1 level. Our finding is different from that of other studies that show that EGCG can decrease HMGB-1 expression [34, 35].

HMGB-1 is secreted actively and passively from cells, active release of HMGB-1 have function to maintain cell and tissue homeostasis and passive release is triggered with insult that threatens the cells. HMGB-1 is a marker of cell damage, and it is released in cells during stress as danger cell signals [8, 36–39]. In response to many stresses or injuries in cells, HMGB-1 is released passively as danger-associated molecular patterns that will trigger inflammation; thus, during acute ischemic stroke, HMGB-1 is released from neuronal cells or other cells in cerebral tissue, and this will accelerate cell injury in cerebral tissue [10, 40]. During acute ischemic stroke, there is increase in free radicals as a result of oxidative stress, and this will increase HMGB-1 levels [41–43]. EGCG as an active compound of green tea has strong antioxidant property and also acts as a free radical scavenger that can decrease the HMGB-1 level [25, 34, 35, 43, 44]. Our study shows that EGCG has no effect on the HMGB-1 level because during acute stroke, there is excessive cell damage not only from necrosis mechanism but also from other forms of cell death; this excessive cell death will let neither green tea extract nor its active compound EGCG to block the release of HMGB-1 from neuronal cells [45, 46]. Our study also found that neuroprotective mechanism of EGCG is not through HMGB-1 pathways [46].

Caspase-3 is a key regulator of apoptotic cell death because it involves in the final common pathway of apoptosis. Our study shows that the high dose of EGCG can inhibit caspase-3 expression, and this implies that the high dose of EGCG can prevent neuronal apoptotic cell death in the MCAO model throughout its inhibition [2, 47]. This result is similar to that of the study by Nan et al. [48] which shows that treatment using EGCG will diminish expression of caspase-3. Some studies also show that EGCG can inhibit apoptosis through its antioxidant activity and as a free radical scavenger [25, 32]. During cerebral ischemia, there is increase in excitatory amino acids, free radicals, NO, and inflammation that will trigger neuronal death including apoptosis. There is increase in mitochondrial function during acute ischemia, which will activate cytochrome c, caspase, and apoptotic bodies. EGCG that has free radical scavenger effect thus will decrease apoptotic cell death [48]. EGCG also stabilized mitochondria through its antioxidant and free radical scavenger properties [49]. Our intervention group treated with standardized green tea extract shows no significant difference compared with the control group; this may be because it needs a higher dose of

EGCG to inhibit apoptosis in the MCAO model because in the EGCG-treated group, significant caspase-3 inhibition is shown only in the group treated with the highest dose of EGCG (30 mg/kg BW).

BCL-2 is a main antiapoptosis protein; it regulates apoptosis through the mitochondrial complex that maintains the integrity of the outer mitochondrial membrane [20, 22]. Expression of BCL-2 is increased in our intervention study, which means that either green tea extract or its active compound EGCG can inhibit apoptosis through increasing BCL-2 expression [48, 50].

There is a different mechanism of EGCG in the context of stroke and malignancy with regard to the effect on apoptosis. Effect of EGCG in malignancy can induce apoptosis; however, in stroke, EGCG can prevent neuronal apoptosis, and this is different because of different expression of *silent information regulator* (SIRT3). EGCG will significantly reduce SIRT3 expression in malignancy, but not in normal cells; thus, EGCG can prevent apoptotic neuronal death [51].

There is no correlation between HMGB-1 and caspase-3 in our study. Zhang et al. [52] studied colorectal cancer and found that increase in HMGB-1 levels will increase activation of caspase-3. Another study also found that HMGB-1 release promotes apoptosis in cancer cells [53]. The role of HMGB-1 in stroke is different between the acute phase and recovery phase. HMGB-1 in the acute phase promotes necrosis and triggers inflammation, but in the recovery phase, HMGB-1 mediates plasticity and recovery [54]. Oxidation of EGCG will produce dimer EGCG (theasinensin) and cause aggregation of HMGB-1 and promote autophagia; in our study, EGCG treatment showed no effect because excessive release of HMGB-1 prevented EGCG from blocking HMGB-1 [46]. In our study, there were no significant correlation between HMGB-1 and caspase-3, this result shows that caspase-3 expression is not through the HMGB-1 pathway [46].

Our study found that antiapoptotic property of EGCG through inhibition of caspase-3 expression and increasing BCL-2 expression. This action may be because of antioxidant property and free radical scavenger effect of EGCG [25, 27, 55]. Neuroprotective effect of EGCG has been demonstrated in many stroke model studies [25, 27, 29, 55]. One of the mechanisms of neuroprotective EGCG is through antiapoptotic effect and properties that can stabilize the mitochondrial membrane [24, 32, 48, 49]. Mitochondria has been long known to play a role in apoptosis through oxidative stress that triggers cytochrome c which can stimulate apoptosis [32].

Our study is a true experimental study using either EGCG as the active compound or green tea extract, giving

new insights into neuroprotective mechanism of EGCG in the stroke model that should continue in clinical trials. Our study is a true experimental trial that we can control other confounding factors that will affect this study.

The limitation of our study is that it is an animal model study that should be proven in clinical trials to know the usefulness in stroke patients. Our study using immunohistochemistry method, resulting in semiquantitative data. For more objective result and assessment we used Allred score.

Conclusions

Green tea treatment with its active compound EGCG inhibits the expression of the neuronal apoptosis marker in the MCAO model and shows no effect on the level of HMGB-1.

Acknowledgments: Gratitude is due to the Head of the Department of Pathology, Faculty of Medicine, Universitas Airlangga, and Head of the Department of Pharmaceutical chemistry, Faculty of Pharmacy, Universitas Airlangga.

Research funding: Research fund was obtained from Research and Community Service Management Information Systems Ministry of Research, Technology, and Higher Education of the Republic of Indonesia.

Author contributions: All authors have accepted responsibility for the entire content of this manuscript and approved its submission.

Competing interests: The authors state no conflict of interest.

Ethical approval: Ethical approval was obtained from The Research Ethics Committee, Faculty of Veterinary Medicine, Universitas Airlangga, number: 2.KE.161.09.2018.

References

1. Sicard K, Fisher M. Animal models of focal brain ischemia. *Exp Transl Stroke Med* 2009;1. <https://doi.org/10.1186/2040-7378-1-7>.
2. Le D, Wu Y, Huang Z, Matsushita K, Plesnila N, Augustinack J, et al. Caspase activation and neuroprotection in caspase-3-deficient mice after in vivo cerebral ischemia and in vitro oxygen glucose deprivation. *Proc Natl Acad Sci U S A* 2002;99:15188–93.
3. Reynolds M, Kirchick H, Dahlen J, Anderberg J, McPherson P, Nakamura K, et al. Early biomarkers of stroke. *Clin Chem* 2003;49: 1733–9.
4. Guo Y, Li P, Guo Q, Shang K, Yan D, Du S, et al. Pathophysiology and biomarkers in acute ischemic stroke – a review. *Trop J Pharmaceut Res* 2014;12:1097.

5. Levine S. Pathophysiology and therapeutic targets for ischemic stroke. *Clin Cardiol* 2004;27:12–24.
6. Lorenzano S, Rost N, Khan M, Li H, Batista L, Chutinet A, et al. Early molecular oxidative stress biomarkers of ischemic penumbra in acute stroke. *Neurology* 2019;93:e1288–98.
7. Deb P, Sharma S, Hassan K. Pathophysiologic mechanisms of acute ischemic stroke: an overview with emphasis on therapeutic significance beyond thrombolysis. *Pathophysiology* 2010;17:197–218.
8. Zhang Q, Kang R, Zeh H III, Lotze M, Tang D. DAMPs and autophagy. *Autophagy* 2013;9:451–8.
9. Luo Y, Li S, Yang J, Qiu Y, Chen F. HMGB1 induces an inflammatory response in endothelial cells via the RAGE-dependent endoplasmic reticulum stress pathway. *Biochem Biophys Res Commun* 2013;438:732–8.
10. Muhammad S, Barakat W, Stoyanov S, Murikinati S, Yang H, Tracey K, et al. The HMGB1 receptor RAGE mediates ischemic brain damage. *J Neurosci* 2008;28:12023–31.
11. Fonken L, Frank M, Kitt M, D'Angelo H, Norden D, Weber M, et al. The alarmin HMGB1 mediates age-induced neuroinflammatory priming. *J Neurosci* 2016;36:7946–56.
12. Bertheloot D, Latz E. HMGB1, IL-1 α , IL-33 and S100 proteins: dual-function alarmins. *Cell Mol Immunol* 2016;14:43–64.
13. Keyel P. How is inflammation initiated? Individual influences of IL-1, IL-18 and HMGB1. *Cytokine* 2014;69:136–45.
14. Lei C, Wu B, Cao T, Zhang S, Liu M. Activation of the high-mobility group box 1 protein-receptor for advanced glycation end-products signaling pathway in rats during neurogenesis after intracerebral hemorrhage. *Stroke* 2015;46:500–6.
15. Portt L, Norman G, Clapp C, Greenwood M, Greenwood M. Anti-apoptosis and cell survival: a review. *Biochim Biophys Acta* 2011;1813:238–59.
16. Saikumar P, Venkatachalam M. Apoptosis and cell death. *Molecular Pathology Library*; 2009:29–40 pp.
17. McIlwain D, Berger T, Mak T. Caspase functions in cell death and disease: figure 1. *Cold Spring Harb Perspect Biol* 2015;7:a026716.
18. Bayir H, Kagan V. Bench-to bedside review: mitochondrial injury, oxidative stress and apoptosis – there is nothing more practical than a good theory. *Crit Care* 2008;12:206.
19. Elmore S. Apoptosis: a review of programmed cell death. *Toxicol Pathol* 2007;35:495–516.
20. Jafari Anarkooli I, Sankian M, Ahmadpour S, Varasteh A, Haghiri H. Evaluation of Bcl-2 family gene expression and caspase-3 activity in hippocampus STZ-induced diabetic rats. *Exp Diabetes Res* 2008;2008:1–6.
21. Wang C, Youle R. The role of mitochondria in apoptosis. *Annu Rev Genet* 2009;43:95–118.
22. Anilkumar U, Prehn J. Anti-apoptotic BCL-2 family proteins in acute neural injury. *Front Cell Neurosci* 2014;8:281.
23. Nikolettou V, Markaki M, Palikaras K, Tavernarakis N. Crosstalk between apoptosis, necrosis and autophagy. *Biochim Biophys Acta* 2013;1833:3448–59.
24. Singh B, Shankar S, Srivastava R. Green tea catechin, epigallocatechin-3-gallate (EGCG): mechanisms, perspectives and clinical applications. *Biochem Pharmacol* 2011;82:1807–21.
25. Zhang J, Xu H, Yuan Y, Chen J, Zhang Y, Lin Y, et al. Delayed treatment with green tea polyphenol EGCG promotes neurogenesis after ischemic stroke in adult mice. *Mol Neurobiol* 2016;54:3652–64.
26. Kim H, Quon M, Kim J. New insights into the mechanisms of polyphenols beyond antioxidant properties; lessons from the green tea polyphenol, epigallocatechin 3-gallate. *Redox Biol* 2014;2:187–95.
27. Lim SH, Kim HS, Kim YK, Kim TM, Im S, Chung ME, et al. The functional effect of epigallocatechin gallate on ischemic stroke in rats. *Acta Neurobiol Exp* 2010;70:40–6.
28. Katz M, Lipton R, Hall C, Zimmerman M, Sanders A, Verghese J, et al. Age-specific and sex-specific prevalence and incidence of mild cognitive impairment, dementia, and Alzheimer dementia in blacks and whites. *Alzheimer Dis Assoc Disord* 2012;26:335–43.
29. Wu K, Hsieh M, Wu C, Wood W, Chen Y. Green tea extract ameliorates learning and memory deficits in ischemic rats via its active component polyphenol epigallocatechin-3-gallate by modulation of oxidative stress and neuroinflammation. *Evid base Compl Alternative Med* 2012;2012:1–11.
30. Zhao C, Li C, Liu S, Yang L. The galloyl catechins contributing to main antioxidant capacity of tea made from *Camellia sinensis* in China. *Sci World J* 2014;2014:1–11.
31. Ran ZH, Xu Q, Tong JL, Xiao SD. Apoptotic effect of Epigallocatechin-3-gallate on the human gastric cancer cell line MKN45 via activation of the mitochondrial pathway. *World J Gastroenterol* 2007;13:4255–9.
32. Yao K, Ye P, Zhang L, Tan J, Tang X, Zhang Y. Epigallocatechin gallate protects against oxidative stress-induced mitochondria-dependent apoptosis in human lens epithelial cells. *Mol Vis* 2008;14:217–23.
33. Allred DC, Bustamante MA, Daniel CO, Gaskill HV, Cruz AB. Immunocytochemical analysis of estrogen receptors in human breast carcinomas: evaluation of 130 cases and review of the literature regarding concordance with biochemical assay and clinical relevance. *Arch Surg* 1990;125:13.
34. Meng X, Li B, Liu S, Kang H, Zhao L, Zhou R. EGCG in green tea induces aggregation of HMGB1 protein through large conformational changes with polarized charge redistribution. *Sci Rep* 2016;6:22128.
35. Li W, Zhu S, Li J, Assa A, Jundoria A, Xu J, et al. EGCG stimulates autophagy and reduces cytoplasmic HMGB1 levels in endotoxin-stimulated macrophages. *Biochem Pharmacol* 2011;81:1152–63.
36. Rosin D, Okusa M. Dangers within: DAMP responses to damage and cell death in kidney disease. *J Am Soc Nephrol* 2011;22:416–25.
37. Kataoka H, Kono H, Patel Z, Rock K. Evaluation of the contribution of multiple DAMPs and DAMP receptors in cell death-induced sterile inflammatory responses. *PLoS One* 2014;9: e104741.
38. Land WG. The role of damage-associated molecular patterns (DAMPs) in human diseases: part II: DAMPs as diagnostics, prognostics and therapeutics in clinical medicine. *Sultan Qaboos Univ Med J* 2015;15:e157–70.
39. Frank M, Weber M, Watkins L, Maier S. Stress sounds the alarmin: the role of the danger-associated molecular pattern HMGB1 in stress-induced neuroinflammatory priming. *Brain Behav Immun* 2015;48:1–7.
40. Kim D, Choi I, Jang H, Lee S. HMGB1 suppression confers neuroprotection against stroke in diabetic rats. *Transl Neurosci* 2013;4. <https://doi.org/10.2478/s13380-013-0145-y>.
41. Rodrigo R, Fernández-Gajardo R, Gutiérrez R, Matamala JM, Carrasco R, Miranda-Merchak A, et al. Oxidative stress and pathophysiology of ischemic stroke: novel therapeutic

- opportunities. *CNS Neurol Disord - Drug Targets* 2013;12:698–714.
42. Lewén A, Fujimura M, Sugawara T, Matz P, Copin J, Chan P. Oxidative stress-dependent release of mitochondrial cytochrome c after traumatic brain injury. *J Cerebr Blood Flow Metabol* 2001;21:914–20.
 43. Yu Y, Tang D, Kang R. Oxidative stress-mediated HMGB1 biology. *Front Physiol* 2015;6. <https://doi.org/10.3389/fphys.2015.00093>.
 44. Kim E, Han S, Hwang K, Kim D, Kim E, Hossain M, et al. Antioxidant and cytoprotective effects of (–)-Epigallocatechin-3-(3″-O-methyl) gallate. *Int J Mol Sci* 2019;20:3993.
 45. Gu M, Liu J, Shi NN, Li XD, Huang ZD, Wu JK, et al. Analysis of property and efficacy of traditional Chinese medicine in staging revention and treatment of coronavirus disease 2019. *Zhongguo Zhongyao Zazhi* 2020;45:1253–8.
 46. Wu A, He L, Long W, Zhou Q, Zhu S, Wang P, et al. Novel mechanisms of herbal therapies for inhibiting HMGB1 secretion or action. *Evid base Compl Alternative Med* 2015; 2015:1–11.
 47. Gill R, Soriano M, Blomgren K, Hagberg H, Wybrecht R, Miss M, et al. Role of caspase-3 activation in cerebral ischemia-induced neurodegeneration in adult and neonatal brain. *J Cerebr Blood Flow Metabol* 2002;22:420–30.
 48. Nan W, Zhonghang X, Keyan C, Tongtong L, Wanshu G, Zhongxin X. Epigallocatechin-3-gallate reduces neuronal apoptosis in rats after middle cerebral artery occlusion injury via PI3K/AKT/eNOS signaling pathway. *BioMed Res Int* 2018;2018:1–9.
 49. Adikesavan G, Vinayagam M, Abdulrahman L, Chinnasamy T. (–)-Epigallocatechin-gallate (EGCG) stabilize the mitochondrial enzymes and inhibits the apoptosis in cigarette smoke-induced myocardial dysfunction in rats. *Mol Biol Rep* 2013;40:6533–45.
 50. Liu L, Ju Y, Wang J, Zhou R. Epigallocatechin-3-gallate promotes apoptosis and reversal of multidrug resistance in esophageal cancer cells. *Pathol Res Pract* 2017;213:1242–50.
 51. Tao L, Park J, Lambert J. Differential prooxidative effects of the green tea polyphenol, (–)-epigallocatechin-3-gallate, in normal and oral cancer cells are related to differences in sirtuin 3 signaling. *Mol Nutr Food Res* 2014;59:203–11.
 52. Zhang Z, Wang M, Zhou L, Feng X, Cheng J, Yu Y, et al. Increased HMGB1 and cleaved caspase-3 stimulate the proliferation of tumor cells and are correlated with the poor prognosis in colorectal cancer. *J Exp Clin Canc Res* 2015;34. <https://doi.org/10.1186/s13046-015-0166-1>.
 53. Tang D, Kang R, Cheh C, Livesey K, Liang X, Schapiro N, et al. HMGB1 release and redox regulates autophagy and apoptosis in cancer cells. *Oncogene* 2010;29:5299–310.
 54. Hayakawa K, Qiu J, Lo E. Biphasic actions of HMGB1 signaling in inflammation and recovery after stroke. *Ann N Y Acad Sci* 2010; 1207:50–7.
 55. Yao C, Zhang J, Liu G, Chen F, Lin Y. Neuroprotection by (–)-epigallocatechin-3-gallate in a rat model of stroke is mediated through inhibition of endoplasmic reticulum stress. *Mol Med Rep* 2013;9:69–72.